Clinical Trial

TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 6, 2023 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective phase II, single arm mono-institutional study conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of the sequential administration of trans-arterial chemo-embolization (TACE) and stereotactic body radiotherapy (SBRT) with immune checkpoint inhibitors in unresectable hepatocellular carcinoma (HCC) patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-07-23.
Trial Details
NCT Number NCT04988945
Lead Sponsor The University of Hong Kong
Conditions HCC
Enrollment 33 participants
Start Date 2020-12-01
Primary Completion 2024-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2023-09-06